Terns Pharmaceuticals, Inc. (TERN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Foster City, CA, United States. Der aktuelle CEO ist Melita Sun Jung.
TERN hat IPO-Datum 2021-02-05, 59 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $4.75B.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes TERN-101, a farnesoid X receptor agonist in Phase IIa trials for NASH; TERN-201, a vascular adhesion protein-1 inhibitor in Phase Ib development; TERN-501, a thyroid hormone receptor beta agonist in Phase I trials; and TERN-601, an oral Glucagon-Like Peptide-1 receptor agonist program targeting NASH and metabolic diseases. Founded in 2016 and headquartered in Foster City, California, Terns is advancing both single-agent and combination therapy candidates to address significant unmet medical needs in metabolic disease treatment.
